Preclinical models of prostate cancer

Patient-derived xenografts, organoids, and other explant models

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Prostate cancer remains a lethal disease. Preclinical cancer models that accurately represent the tumors of the patients they are intended to help are necessary to test potential therapeutic approaches and to better translate research discoveries. However, research in the prostate cancer field is hampered by the limited number of human cell lines and xenograft models, most of which do not recapitulate the human disease seen in the clinic today. This work reviews the recent advances in human patient-derived xenograft, organoid, and other explant models to address this need. In contrast to other tumor streams, the prostate cancer field is challenged by this approach, yet despite the limitations, patient-derived models remain an integral component of the preclinical testing pathway leading to better treatments for men with prostate cancer.

Original languageEnglish
Article numbera030536
Number of pages14
JournalCold Spring Harbor Perspectives in Medicine
Volume8
Issue number8
DOIs
Publication statusPublished - 1 Aug 2018

Cite this

@article{9415a59b6d33404787bb7082aeaefec3,
title = "Preclinical models of prostate cancer: Patient-derived xenografts, organoids, and other explant models",
abstract = "Prostate cancer remains a lethal disease. Preclinical cancer models that accurately represent the tumors of the patients they are intended to help are necessary to test potential therapeutic approaches and to better translate research discoveries. However, research in the prostate cancer field is hampered by the limited number of human cell lines and xenograft models, most of which do not recapitulate the human disease seen in the clinic today. This work reviews the recent advances in human patient-derived xenograft, organoid, and other explant models to address this need. In contrast to other tumor streams, the prostate cancer field is challenged by this approach, yet despite the limitations, patient-derived models remain an integral component of the preclinical testing pathway leading to better treatments for men with prostate cancer.",
author = "Risbridger, {Gail P.} and Roxanne Toivanen and Taylor, {Renea A.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1101/cshperspect.a030536",
language = "English",
volume = "8",
journal = "Cold Spring Harbor Perspectives in Medicine",
issn = "2157-1422",
number = "8",

}

TY - JOUR

T1 - Preclinical models of prostate cancer

T2 - Patient-derived xenografts, organoids, and other explant models

AU - Risbridger, Gail P.

AU - Toivanen, Roxanne

AU - Taylor, Renea A.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Prostate cancer remains a lethal disease. Preclinical cancer models that accurately represent the tumors of the patients they are intended to help are necessary to test potential therapeutic approaches and to better translate research discoveries. However, research in the prostate cancer field is hampered by the limited number of human cell lines and xenograft models, most of which do not recapitulate the human disease seen in the clinic today. This work reviews the recent advances in human patient-derived xenograft, organoid, and other explant models to address this need. In contrast to other tumor streams, the prostate cancer field is challenged by this approach, yet despite the limitations, patient-derived models remain an integral component of the preclinical testing pathway leading to better treatments for men with prostate cancer.

AB - Prostate cancer remains a lethal disease. Preclinical cancer models that accurately represent the tumors of the patients they are intended to help are necessary to test potential therapeutic approaches and to better translate research discoveries. However, research in the prostate cancer field is hampered by the limited number of human cell lines and xenograft models, most of which do not recapitulate the human disease seen in the clinic today. This work reviews the recent advances in human patient-derived xenograft, organoid, and other explant models to address this need. In contrast to other tumor streams, the prostate cancer field is challenged by this approach, yet despite the limitations, patient-derived models remain an integral component of the preclinical testing pathway leading to better treatments for men with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85051416115&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a030536

DO - 10.1101/cshperspect.a030536

M3 - Article

VL - 8

JO - Cold Spring Harbor Perspectives in Medicine

JF - Cold Spring Harbor Perspectives in Medicine

SN - 2157-1422

IS - 8

M1 - a030536

ER -